公开(公告)号：US20160375050A1

公开(公告)日：2016-12-29

申请号：US15264551

申请日：2016-09-13

Applicant: The Board of Regents of the University of Texas System

Inventor： Gabriel LOPEZ-BERESTEIN ,  Eylem GÜVEN ,  Angela SANGUINO ,  Anil K. SOOD ,  Emir Baki DENKBAS

IPC: A61K31/722 ,  A61K47/02 ,  A61K31/713 ,  A61K31/575 ,  C12N15/113 ,  A61K45/06

CPC classification number: A61K31/722 ,  A61K9/5115 ,  A61K9/5161 ,  A61K9/5192 ,  A61K31/575 ,  A61K31/713 ,  A61K45/06 ,  A61K47/02 ,  A61K47/36 ,  C12N15/1137 ,  C12N2310/14 ,  C12N2320/31 ,  C12N2320/32 ,  C12Y201/01043

Abstract: Disclosed are nanoparticles for the delivery of a therapeutic agent or a diagnostic agent to a subject that include a chitosan and a polyphosphate, wherein the weight ratio of the chitosan to the polyphosphate is about 1.0 or greater and the weight ratio of the polyphosphate to the therapeutic agent or diagnostic agent is about 15.0 or less. Also disclosed are nanoparticles that include a chitosan and an inhibitor of enhancer of Zeste homologue 2 (EZH2). Methods of delivering a therapeutic agent or a diagnostic agent to a subject for the treatment or prevention of a disease and methods of predicting prognosis of ovarian cancer in a subject that involve determining the expression and/or function of EZH2 in the subject are also disclosed.

Abstract translation: 公开了用于将治疗剂或诊断剂递送至包含壳聚糖和多磷酸盐的受试者的纳米颗粒，其中壳聚糖与多磷酸盐的重量比为约1.0或更大，并且多磷酸盐与治疗剂的重量比 药剂或诊断剂的含量约为15.0或更低。 还公开了包含壳聚糖和Zeste同系物2（EZH2）增强子抑制剂的纳米颗粒。 还公开了将治疗剂或诊断剂递送到受试者以治疗或预防疾病的方法以及预测受试者中涉及确定受试者中EZH2的表达和/或功能的卵巢癌预后的方法。